Department of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, CA, United States of America.
Monogram Biosciences, South San Francisco, CA, United States of America.
PLoS One. 2019 Apr 10;14(4):e0213409. doi: 10.1371/journal.pone.0213409. eCollection 2019.
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broadly neutralizing antibodies (bNAbs). While remarkable progress has been made in the isolation and characterization of bNAbs, the epitopes they recognize appear to be poorly immunogenic. Thus, none of the candidate vaccines developed to date has induced satisfactory levels of neutralizing antibodies to the HIV envelope protein (Env). One approach to the problem of poor immunogenicity is to build vaccines based on envelope (env) genes retrieved from rare individuals termed elite neutralizers (ENs) who at one time possessed specific sequences that stimulated the formation of bNAbs. Env proteins selected from these individuals could possess uncommon, yet to be defined, structural features that enhance the immunogenicity of epitopes recognized by bNAbs. Here we describe the recovery of envs from an EN that developed unusually broad and potent bNAbs. As longitudinal specimens were not available, we combined plasma and provirus sequences acquired from a single time-point to infer a phylogenetic tree. Combining ancestral reconstruction data with virus neutralization data allowed us to sift through the myriad of virus quasi-species that evolved in this individual to identify envelope sequences from the nodes that appeared to define the transition from neutralization sensitive envs to the neutralization resistant envs that occur in EN plasma. Synthetic genes from these nodes were functional in infectivity assays and sensitive to neutralization by bNAbs, and may provide a novel source of immunogens for HIV vaccine development.
HIV 疫苗开发的一个主要挑战是鉴定能够引发广泛中和抗体 (bNAb) 的免疫原。虽然在分离和鉴定 bNAb 方面取得了显著进展,但它们识别的表位似乎免疫原性较差。因此,迄今为止开发的候选疫苗都没有诱导出令人满意的 HIV 包膜蛋白 (Env) 中和抗体水平。解决免疫原性差问题的一种方法是基于从称为精英中和者 (EN) 的罕见个体中回收的包膜 (env) 基因构建疫苗,这些个体在某一时刻具有刺激 bNAb 形成的特定序列。从这些个体中选择的 Env 蛋白可能具有不常见但尚未定义的结构特征,从而增强 bNAb 识别表位的免疫原性。在这里,我们描述了从一个产生异常广泛和有效 bNAb 的 EN 中回收 envs 的过程。由于没有纵向标本,我们将从单个时间点获得的血浆和前病毒序列组合在一起,以推断出系统发育树。将祖先重建数据与病毒中和数据相结合,使我们能够从个体中进化出的无数病毒准种中筛选出似乎定义从中和敏感 Env 向 EN 血浆中出现的中和抗性 Env 转变的包膜序列。来自这些节点的合成基因在感染性测定中具有功能,并且对 bNAb 的中和敏感,可能为 HIV 疫苗开发提供新的免疫原来源。